For how we live.
An updated systematic review of 25 randomised trials found small effects, concentrated in neuropathic pain, alongside moderate to large increases in dizziness, sedation and nausea. Long-term data barely exist.
Anvisa's five new resolutions build a controlled supply chain from seed to shelf, including a regulatory sandbox for patient associations. Analysts say the framework's biggest gap is the one it did not close.
Ten weeks of a legal broad-spectrum CBD product produced detectable cannabigerol and cannabidivarin in most participants. After a 90-minute ride, detection rates rose to 74% and 84%.